Activated thrombin-activable fibrinolysis inhibitor (TAFIa) plays a significant role in the prolongation of fibrinolysis. During fibrinolysis, plasminogen is activated to plasmin, which lyses a clot by cleaving fibrin after selected arginine and lysine residues. TAFIa attenuates fibrinolysis by removing the exposed C-terminal lysine residues. It was recently reported that TAFI zymogen possesses sufficient carboxypeptidase activity to attenuate fibrinolysis through a mechanism similar to TAFIa. Here, we show with a recently developed TAFIa assay that when thrombin is used to clot TAFI-deficient plasma supplemented with TAFI, there is some TAFI activation. The extent of activation was dependent upon the concentration of zymogen present in the plasma, and lysis times were prolonged by TAFIa in a concentration-dependent manner. Potato tuber carboxypeptidase inhibitor, an inhibitor of TAFIa but not TAFI, abolished the prolongation of lysis in TAFI-deficient plasma supplemented with TAFI zymogen. In addition, TAFIa but not TAFI catalyzed release of plasminogen bound to soluble fibrin degradation products. The data presented confirm that TAFI zymogen is effective in cleaving a small substrate but does not play a role in the attenuation of fibrinolysis because of its inability to cleave plasmin-modified fibrin degradation products.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276372 | PMC |
| http://dx.doi.org/10.1074/jbc.M800127200 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential.
Res Pract Thromb Haemost
May 2024
Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada.
Background: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that provides a molecular link between coagulation and fibrinolysis. Studies have shown that the presence of glycosaminoglycans accelerates TAFI activation by plasmin and stabilizes activated TAFI (TAFIa).
Objectives: We aimed to define the elements of TAFI structure that allow these effects.
Elevated plasma factor XI is associated with postthrombotic syndrome.
Thromb Res
September 2024
Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Centre for Medical Research and Technologies, St. John Paul II Hospital, Krakow, Poland. Electronic address:
Article Synopsis
- Postthrombotic syndrome (PTS) is a common inflammatory complication that arises after deep vein thrombosis (DVT), and this study investigates the role of elevated factor XI (FXI) in the occurrence of PTS.
- Researchers measured FXI levels and several inflammatory and clot-related markers in 180 patients with first-time DVT, finding a significant association between higher FXI levels and the severity of PTS symptoms as measured by the Villalta score.
- The study concludes that increased FXI, linked to inflammation and clot properties, may play a crucial role in the development of PTS, with implications for both PTS occurrence and the recurrence of venous thromboembolism (VTE).
Brain Expression of CPB2 and Effects of Cpb2 Deficiency in Mouse Models of Behavior.
Thromb Haemost
January 2024
Division of Hematology, Stanford University School of Medicine, Stanford, California, United States.
Background: Procarboxypeptidase B2 (proCPB2 or TAFI) is a zymogen that after activation cleaves C-terminal basic residues from peptides or proteins with many identified targets. A splice variant of CPB2 has been found in the brain lacking essential residues for its carboxypeptidase function. The aim was to determine CPB2 expression in the brain and effects of CPB2 deficiency ( ) on behavior.
View Article and Find Full Text PDFInvestigation of cofactor activities of endothelial microparticle-thrombomodulin with liposomal surrogate.
Biochem Biophys Res Commun
April 2023
Department of Chemistry, Chemical and Biomedical Engineering, Center for Gene Regulation in Health and Disease (GRHD), Cleveland State University, Cleveland, OH, 44115, USA. Electronic address:
Thrombomodulin (TM) is a type I transmembrane glycoprotein mainly expressed on the endothelial cells, where it binds thrombin to form the thrombin-TM complex that can activate protein C and thrombin-activable fibrinolysis inhibitor (TAFI) and induce anticoagulant and anti-fibrinolytic reactions, respectively. Cell activation and injury often sheds microparticles that contain membrane TM, which circulate in biofluids like blood. However, the biological function of circulating microparticle-TM is still unknown even though it has been recognized as a biomarker of endothelial cell injury and damage.
View Article and Find Full Text PDFElucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
J Trauma Acute Care Surg
June 2023
From the Department of Surgery (J.R.C., E.E.M., M.J.C., A.B., C.C.S.), University of Colorado-Denver, Aurora; Department of Surgery (E.E.M.), Ernest E Moore Shock Trauma Center at Denver Health; Department of Cell Biology (K.J.), University of Oklahoma; Vitalant Research Institute (M.R.K.); and Department of Pediatrics (C.C.S.), School of Medicine, University of Colorado Denver, Aurora, Colorado.
Background: The mechanisms underlying trauma-induced coagulopathy remain elusive. Hyperfibrinolysis has been linked to increased plasminogen activation and antiprotease consumption; however, the mechanistic players in its counterpart, fibrinolysis shutdown, remain unclear. We hypothesize that thrombin-activatable fibrinolysis inhibitor (TAFI) plays a major role in fibrinolytic shutdown after injury.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!